---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-005649"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2025-01-14T23:59:59+00:00"
generated_at: "2026-05-28T02:05:35.048297+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "low"
source: SEC EDGAR
---

# UroGen Pharma furnishes January 2025 corporate presentation; no material new disclosures

## Summary
- Presentation reiterates UGN-102 PDUFA target date of June 13, 2025 and planned ODAC meeting.
- Highlights ongoing Phase 3 UTOPIA study for UGN-103 and planned Phase 3 for UGN-104.
- No new financial data or material changes disclosed.

## SEC filing metadata
- accession: 0001193125-25-005649
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2025-01-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000119312525005649/0001193125-25-005649-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000119312525005649/d903812d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-005649
- JSON: https://secwatch.observer/filing/0001193125-25-005649.json
- Plain text: https://secwatch.observer/filing/0001193125-25-005649.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.